[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Monastir\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":404},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,42,66,93,123,148,175,202,224,250,273,305,331,356,381],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100638238","phase-3-outpatient-hypertonic-saline-and-loop-diuretic-combination-therapy-in-cardiorenal-100638238",false,"NCT07596329","Outpatient Hypertonic Saline and Loop Diuretic Combination Therapy in Cardiorenal","Outpatient Hypertonic Saline and Loop Diuretic Combination Therapy in Cardiorenal Syndrome: The SALT-HF Randomized Double-Blind Trial","SALT-HF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Chronic renal insufficiency (serum creatinine \\> 150 µg\u002Fml)\n* Diagnosis of heart failure (preserved or reduced LVEF)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Severe hyponatremia (\\\u003C130 mmol\u002FL) or hypernatremia (\\>150 mmol\u002FL),\n* History of allergic reaction to HSS or furosemide\n* Shock or hemodynamic instability\n* Pregnancy or breastfeeding\n* Chronic dialysis treatment\n* Patient refusal or withdrawal of consent","ALL","18 Years","90 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Congestive heart failure (CHF) remains a major cause of morbidity, rehospitalization, and mortality worldwide, particularly among elderly and polymorbid patients. Systemic congestion is its most characteristic clinical manifestation and the leading cause of hospitalization for acute heart failure. Standard treatment relies on loop diuretics, primarily furosemide, to reduce fluid overload and alleviate congestive symptoms. However, in clinical practice, many patients exhibit an inadequate diuretic response or resistance to furosemide, particularly in the context of cardiorenal syndrome (CRS), where cardiac and renal dysfunction mutually exacerbate each other. This profile, frequently observed in advanced stages of heart failure, significantly limits the effectiveness of guideline-directed medical therapies (GDMTs), particularly SGLT2 inhibitors, mineralocorticoid receptor antagonists, and angiotensin-converting enzyme (ACE) inhibitors, whose use is often restricted by hypotension, hyperkalemia, or impaired renal function.\n\nThus, in this subgroup of patients, conventional pharmacological approaches encounter a therapeutic barrier, necessitating the search for alternative or complementary strategies targeting sodium and water depletion without compromising renal perfusion. In this context, the combined administration of hypertonic saline (HS) and furosemide has been proposed as a pathophysiologically sound approach to break the vicious cycle of cardiorenal syndrome. Hypertonic saline solution (HSS) acts by restoring effective intravascular volume, improving renal perfusion, and promoting more efficient natriuresis through better furosemide delivery to the distal nephron. Pioneering studies by Paterna et al. showed that the concomitant administration of HSS (1.4-3% NaCl, 150-250 mL) and intravenous furosemide increased diuresis, improved the hemodynamic profile, and reduced the length of hospital stay and readmission rates without deterioration of renal function.",[28,29],"Heart Failure","Renal Disease, Chronic","NOT_YET_RECRUITING","2026-05-18",{"date":33,"type":34},"2026-05-19","ACTUAL",{"date":36,"type":22},"2026-05-01",{"date":38,"type":22},"2027-12-30",{"name":40,"class":41},"University of Monastir","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100591461","phase-3-comparative-efficacy-of-iv-dexamethasone-vs-nebulized-terbutaline-for-renal-colic-pain-in-the-ed-100591461","NCT06980727","Comparative Efficacy of IV Dexamethasone vs. Nebulized Terbutaline for Renal Colic Pain in the ED","Increment Value of Intravenous Dexametasone Versus Nebulized Terbutaline for Renal Colic Pain Management in the Emergency Department: A Randomized Clinical Trial","Inclusion criteria:\n\n* Adults aged 18-65 years\n* Clinical diagnosis of acute renal colic (defined as sudden sharp colicky flank pain with or without radiation to the genitalia or groin, and with or without urinary symptoms)\n* Pain score of 5 or more measured using the 10-cm NRS scale\n\nExclusion Criteria:\n\n* History of cardiovascular, hepatic, renal, or metabolic diseases\n* Evidence of sepsis or clinical suspicion of urinary tract infection\n* Hemodynamically unstable (systolic blood pressure \\\u003C 90 mmHg)\n* Uncontrolled diabetes\n* Pregnancy or breastfeeding\n* Inability to understand verbal and\u002For written information\n* Received any analgesics within 6 hours prior to presentation\n* Serum potassium \\\u003C 3.7 mmol\u002FL\n* Concomitant use of:\n\nAny beta-blockers (including beta-blocker-containing eye drops)\n\nProlonged-release long-acting β-agonists\n\nShort-acting β2-agonists within 6 hours prior to presentation\n\n* Contraindication to terbutaline use\n* Known allergy to paracetamol or terbutaline\n* Abdominal tenderness suggestive of peritoneal inflammation\n* Clinical suspicion of conditions other than urolithiasis, including:\n* Abdominal aortic aneurysm\n* Aortic dissection\n* History of drug dependence or chronic alcohol consumption","65 Years",{"count":51,"type":22},300,[25],"Adult patients (18-55 years of age) with clinical diagnosis of acute renal colic (sudden sharp colic flank pain with or without radiation to genitalia or groin and with or without urinary symptoms) who had pain score of 5 or more measured by 10-cm visual analogue scale (VAS), will be included. Will be excluded those who had history of cardiovascular, hepatic, renal or metabolic diseases, patients with evidence of sepsis or clinical suspicion of urinary tract infection, hemodynamically unstable patients (systolic blood pressure \\<90 mmHg), patients with uncontrolled diabetes, pregnancy, breastfeeding, patients unable to understand verbal and\u002For written information, patients receiving analgesics within 6 hours before presentation, serum potassium less than 3.7 mmol\u002Fl, concomitant use of any beta blockers (including beta-blocker containing eye drops), prolonged-release long-acting β-agonists, use of short-acting β2-agonists within the 6 h preceding presentation to the emergency department, any contraindication to the use of terbutaline, history of drug dependence or chronic consumption of alcohol. Will be also excluded patients with known allergy to paracetamol or terbutaline, patients with abdominal tenderness as a sign of peritoneal inflammation and those with any clinical suspicion for diseases other than urolithiasis, including abdominal aortic aneurysm or dissection.",[55],"Renal Colic",[55,57],"Dexamethasone",{"date":59,"type":34},"2026-05-20",{"date":61,"type":22},"2026-08-08",{"date":63,"type":22},"2028-03-01",{"name":40,"class":41},1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100639288","mindfulness-plus-supervised-rehabilitation-vs-supervised-rehabilitation-alone-for-chronic-neck-pain-in-office-workers-100639288","NCT07576556","Mindfulness Plus Supervised Rehabilitation vs Supervised Rehabilitation Alone for Chronic Neck Pain in Office Workers","Effect of Mindfulness Combined With Supervised Rehabilitation Versus Supervised Rehabilitation Alone in Office Workers With Chronic Neck Pain: Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n* Office workers aged 18 years or older\n* diagnosed with chronic neck pain for more the three months\n\nExclusion Criteria:\n\n* history of neck surgery\n* history of cervical trauma\n* history of neurological disorders affecting the neck or upper extremities\n* currently receiving other treatments for neck pain, such as injections or surgical interventions\n* Participants with significant psychiatric disorders that could interfere with study participation or adherence to the intervention",{"count":74,"type":22},48,[76],"NA","The goal of this clinical trial is to learn if adding mindfulness to supervised rehabilitation exercises improves outcomes in office workers with chronic neck pain. It will also evaluate the impact of this combined approach on psychosocial factors and quality of life. The main questions it aims to answer are:\n\nDoes mindfulness combined with supervised exercises reduce neck pain intensity more than supervised exercises alone? Does the combined intervention improve neck-related disability, psychosocial outcomes, and quality of life?\n\nResearchers will compare a mindfulness-based intervention plus supervised rehabilitation exercises to supervised rehabilitation exercises alone to determine whether the combined approach provides additional benefit.\n\nParticipants will:\n\nBe randomly assigned to receive either mindfulness plus supervised exercises or supervised exercises alone for 8 weeks Attend weekly 60-minute mindfulness sessions (experimental group only) and twice-weekly supervised exercise sessions Undergo assessments at the beginning and at the end of the intervention period",[79],"Chronic Neck Pain",[81,82,83,84,85],"office workers","supervised exercise","neck pain","stress","mindfulness","2026-05-02",{"date":88,"type":34},"2026-05-08",{"date":36,"type":22},{"date":91,"type":22},"2026-12-31",{"name":40,"class":41},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":65},"100619479","congestion-and-lactate-at-discharge-in-acute-heart-failure-100619479","NCT07345156","Congestion and LActate at diScHarge in Acute Heart Failure","Validation of a Combined Score Combining the Lung Ultrasound Score and Lactate at Discharge for Predicting Early Events After Acute Heart Failure","CLASH-HF","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Hospitalization for acute heart failure\u002Fdecompensation (clinical diagnosis + imaging\u002Flaboratory tests according to local practice).\n* Patient deemed ready for discharge (decision made by the team, discharge within 24 hours).\n\nExclusion Criteria:\n\n* Septic shock\u002Fsevere active infection at the time of discharge.\n* Hypoxemia or respiratory distress requiring high-flow oxygen\u002Fventilation at the scheduled time of discharge.\n* Severe cirrhosis\u002Fadvanced liver failure.\n* Refusal to participate.\n* Technical impossibility of LUS.",{"count":102,"type":22},350,"OBSERVATIONAL","Acute heart failure (AHF) is a leading cause of hospitalization and is associated with high short-term morbidity and mortality, with 20-30% of patients experiencing rehospitalization or death within 30 days. Early adverse events often reflect incomplete recovery, highlighting the need for improved risk stratification after clinical stabilization .Current prognostic approaches mainly focus on hemodynamic congestion. Persistent pulmonary congestion at discharge is a strong predictor of poor outcomes, but these markers primarily assess macrocirculatory abnormalities and do not capture microcirculatory dysfunction, which may persist despite apparent clinical improvement. Lung ultrasound, through the Lung Ultrasound Score (LUS), provides a validated assessment of pulmonary congestion and has demonstrated prognostic value in AHF. However, LUS does not reflect systemic tissue perfusion. In contrast, blood lactate is a robust marker of tissue hypoperfusion, and even mild elevations have been associated with worse outcomes in AHF. A combined score integrating LUS and lactate may therefore better reflect the dual pathophysiology of AHF-persistent congestion and impaired tissue perfusion-and improve prediction of early adverse events.\n\nThis protocol aims to validate the prognostic value of this combined score for predicting 30-day rehospitalization or death in patients hospitalized for AHF, with the hypothesis that it outperforms LUS alone.",[106,107,108],"Heart Failure Acute","Discharge Follow-up Phone Calls","Mortality Prediction",[110,111,112,113,114],"Lung Ultrasound Score","Lactate","Combined score","Acute Heart Failure","Discharge","2026-01-08",{"date":117,"type":34},"2026-01-15",{"date":119,"type":22},"2026-01-01",{"date":121,"type":22},"2026-12-30",{"name":40,"class":41},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":134,"studyType":103,"phases":4,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":65},"100347685","short-and-long-term-prognosis-of-patients-admitted-to-the-ed-with-acute-heart-failure-100347685","NCT03806972","Short and Long Term Prognosis of Patients Admitted to the ED With Acute Heart Failure","Short and Long Term Prognosis of Patients Admitted to the Emergency Department With Acute Heart Failure","CRF","Inclusion Criteria:\n\n* patients admitted to the ED of Monastir with a principal discharge diagnosis code for HF.\n\nExclusion Criteria:\n\n* Pregnant or breast feeding women. Alteration of consciousness GCS \\\u003C 15 Critically ill patients needing immediate mechanical hemodynamic of ventilatory support.\n\nInability to follow instructions or comply with follow-up procedures.","80 Years",{"count":133,"type":22},3000,"12 Months","Heart failure (HF) is the leading cause of hospitalization ,rehospitalization and mortality for adults over 65 years of age.\n\nThis study aimed to assess mortality, and hospitalization rates at 30 days and one year after dicharge of patients with heart failure (HF) with reduced ejection fraction (HFrEF) compared to HF with preserved ejection fraction (HFpEF).",[113],[138],"acute heart failure prognosis","RECRUITING","2025-07-17",{"date":142,"type":34},"2025-07-22",{"date":144,"type":34},"2009-06-01",{"date":146,"type":22},"2030-12-01",{"name":40,"class":41},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":65},"100485794","phase-2-olive-leaf-extracts-in-the-control-of-diabet-100485794","NCT05605704","Olive Leaf Extracts in the Control of Diabet","Efficacy of a Treatment Based on Olive Leaf Extracts in the Control of Diabet","Dia-Athr","Inclusion Criteria:\n\n* Patients over 18 years of age with:\n* diabetes.\n\nExclusion Criteria:\n\n* Exclusion criteria: None.","100 Years",{"count":158,"type":22},500,[160,25],"PHASE2","This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital).\n\nPatients over 18 years of age with:\n\n-Diabets",[163],"Diabetes Mellitus, Type 2",[165,166],"diabetes","Atherolive","2025-06-01",{"date":169,"type":34},"2025-06-03",{"date":171,"type":34},"2023-01-01",{"date":173,"type":22},"2025-12-15",{"name":40,"class":41},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100571649","phase-2-effect-of-olive-leaf-extracts-on-endothelial-dysfunction-in-patients-with-acute-coronary-syndrome-100571649","NCT06723002","Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome","Effect of Olive Leaf Extracts on Endothelial Dysfunction and Short-term Outcome in Patients With Acute Coronary Syndrome","ACS_ATHEROLIV","Inclusion Criteria:\n\nAge over 18 years. Patients presenting with ST-segment alterations at rest, including ST elevation, with or without troponin elevation.\n\nPatients who have not undergone surgery or have no additional primary percutaneous coronary intervention (P-PCI) planned within 8 weeks from the initial P-PCI.\n\nPatients who provide informed consent. Patients available for and willing to adhere to follow-up procedures. Patients without significant cognitive impairment. Patients with a life expectancy of at least 2 years.\n\nExclusion Criteria:\n\n* Severe LV hypertrophy (\\>15 mm);\n* Patients with any evidence of inflammatory or malignant disease.\n* Patient having valvular heart disease, pacemaker; cardiogenic shock\n* Patient having any serious non-cardiac disease associated with a life expectancy \\\u003C1 year\n* Patients undergoing surgery within 30 days\n* Patient having gastrointestinal disorder such as Crohn's disease",{"count":51,"type":22},[160,25],"the study aims to examine the short-term (30 days) effects of olive leaf extract on endothelial function in patients with acute coronary syndrome (ACS).\n\nThis investigation will be conducted on patients admitted to the emergency department for ACS. All participants will be screened and included within 24 hours post-ACS event and prior to discharge from the emergency department.",[187,188,189],"Acute Coronary Syndrome (ACS)","Reactive Hyperemia","Endothelial Dysfunction",[191,192,193],"acute conary syndrome","endothelial dysfunction","olive leaf extract","2024-12-03",{"date":196,"type":34},"2024-12-09",{"date":198,"type":22},"2024-12-01",{"date":200,"type":22},"2025-12-30",{"name":40,"class":41},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":166,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":65},"100488185","phase-2-olive-leaf-extracts-in-the-control-of-hypertension-100488185","NCT05636826","Olive Leaf Extracts in the Control of Hypertension","Efficacy of a Treatment Based on Olive Leaf Extracts in the Control of Cardiovascular Risk Factors:Hypertension","Inclusion Criteria:\n\n* patients over 18 years of age with:\n\nArterial hypertension (hypertension)\n\nExclusion Criteria:\n\n* . Exclusion criteria: None.","95 Years",{"count":158,"type":22},[160,25],"This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital).\n\nPatients over 18 years of age with:\n\nArterial hypertension (hypertension).",[214],"Hypertension",[216],"hypertension","2024-11-05",{"date":219,"type":34},"2024-11-08",{"date":221,"type":34},"2023-12-30",{"date":200,"type":22},{"name":40,"class":41},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":65},"100542657","phase-2-paracetamol-tramadol-and-paracetamol-caffeine-versus-placebo-in-the-emergency-discharge-treatment-of-renal-colic-100542657","NCT06345716","Paracetamol-Tramadol and Paracetamol-caffeine Versus Placebo in the Emergency Discharge Treatment of Renal Colic","RC","Inclusion Criteria:\n\n* -Age \\> 18 years old.\n* Consent to participate in the study.\n* Pain in the flank\u002Flumbar fossa of sudden onset with urine strips and\u002For imaging corresponding to the diagnosis of renal colic.\n* Pain score at discharge \\\u003C 30 (visual analog scale - VAS or verbal numerical scale - VAS from 0 to 100).\n\nExclusion Criteria:\n\n* -Inability to appreciate pain according to the VAS.\n* Pregnant or breastfeeding woman.\n* Renal insufficiency with creatinine clearance \\\u003C 60 ml\u002Fmin.","99 Years",{"count":233,"type":22},1500,[160],"This is a prospective, randomized, single-blind study. Patients included in the study after successful treatment of the acute attack were randomized upon discharge from the Emergency Department into three groups: oral paracetamol-tramadol group, oral paracetamol-caffeine group and oral placebo group.",[55],[238,239,240,241],"renal colic","paracetamol-tramadol","paracetamol-cafeine","placebo","2024-09-11",{"date":244,"type":34},"2024-09-19",{"date":246,"type":34},"2024-04-10",{"date":248,"type":22},"2025-11-30",{"name":40,"class":41},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},"100467652","early-phase-1-mini-bolus-for-fluid-challenge-responsiveness-in-the-emergency-department-100467652","NCT05369559","Mini Bolus for Fluid Challenge Responsiveness in the Emergency Department","MIBORED","Inclusion Criteria:\n\n* Patients with spontaneous breathing\n* Patients in whom a fluid challenge is indicated because they present acute circulatory failure (which is defined as systolic blood pressure less than 90 mmHg or the need for vasopressors (norepinephrine more than 0.1 µg\u002Fkg\u002Fmin) to maintain a systolic blood pressure more than 90 mmHg (14), and at least one sign of inadequate tissue perfusion:\n\n  * urine output of below 0.5ml\u002Fkg per hour over 1 hour\n  * tachycardia (heart rate of greater than 100 beats per minute)\n  * mottled skin.\n  * lactate \\> 2 mmol\u002Fl\n\nExclusion Criteria:\n\n* Cardiac arrest\n* Acute respiratory distress syndrome\n* Coma Glasgow Scale \\\u003C 14\n* Age of less than 18 years\n* Moribund patients\n* Pregnant patients\n* impossibility to perform passive leg raising (PLR) (trauma patients, lower extremity amputees, and prone patients)\n* Patients with cardiac arrhythmias\n* Patients with cardiogenic pulmonary oedema",{"count":258,"type":22},1000,[260],"EARLY_PHASE1","Intravascular volume expansion is a common intervention in critically ill patients with acute circulatory failure.we test the hypothesis that a mini-bolus fluid challenge, of either 50 ml , can predict fluid responsiveness in spontaneously breathing patients with hemodynamic instability.",[263],"Fluid Therapy","2024-07-04",{"date":266,"type":34},"2024-07-09",{"date":268,"type":34},"2022-03-03",{"date":270,"type":22},"2025-05-22",{"name":40,"class":41},2,{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":280,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100553416","ai-mobile-app-vs-self-exercises-in-workers-with-neck-pain-100553416","NCT06485804","AI Mobile App vs Self Exercises in Workers With Neck Pain","Comparing Efficacy and Adherence of Smartphone-guided Exercises to Conventional Self-directed Exercises for Neck Pain in Office Workers: A Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n* The presence of a chronic NP lasting for more than three months, and a pain level at baseline assessment ≥ 30 (VAS)\n\nExclusion Criteria:\n\n* Acute neck pain, neck pain from specific causes (eg; Chronic inflammatory diseases), spine trauma or surgery, cervical radiculopathy or myelopathy, and physical therapy treatments in the last six months before baseline assessment.","30 Years","63 Years",{"count":283,"type":22},34,[76],"This study aims to compare the impact of two different methods to administer self-exercises in administrative workers with neck pain: an Artificial Intelligence embedded mobile application and written sheet.",[287,288],"Neck Pain","Work-Related Condition",[290,291,292,293,287,294,295,296],"Office Workers","Clinical trial Protocol","Exercise Therapy","Mobile Application","Patient compliance","Self-management","Workplace","2024-07-01",{"date":299,"type":34},"2024-07-03",{"date":301,"type":22},"2024-07-15",{"date":303,"type":22},"2024-10-31",{"name":40,"class":41},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":311,"sex":17,"minAge":18,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":4},"100551250","mrna-expression-and-genetic-polymorphisms-affecting-drd3-rs6280-and-htr2a-rs6313-in-bruxism-100551250","NCT06457646","mRNA Expression and Genetic Polymorphisms Affecting DRD3 (rs6280) and HTR2A (rs6313) in Bruxism","Inclusion Criteria:\n\n* be above 18 years of age and have a confirmed diagnosis of bruxism\n\nExclusion Criteria:\n\n* Systemic diseases,\n* orofacial dysfunction,\n* acute symptoms such as neurodegenerative diseases (specifically Parkinsons disease),\n* Taking medication such as anxiolytics",true,"60 Years",{"count":314,"type":22},169,"The goal of this observational study is to learn about the genetic factors influencing bruxism, a condition characterized by teeth grinding, in a group of participants. The main questions it aims to answer are:\n\n* Is there a significant association between the rs6313 polymorphism of the HTR2A gene and bruxism?\n* Is there a significant association between the rs6280 polymorphism of the DRD3 gene and bruxism?\n\nParticipants will:\n\nProvide DNA samples for genotyping of the DRD3 (rs6280) and HTR2A (rs6313) polymorphisms.\n\nProvide RNA samples to assess changes in the expression of HTR2A and DRD3. Researchers will compare the genetic data and RNA expression levels between individuals with bruxism and those without (controls) to see if there are significant genetic differences and expression changes associated with bruxism.",[317],"Bruxism",[319,317,320,321,322],"Gene Expression","Sleep bruxism","Polymorphism","Genetic","2024-06-08",{"date":325,"type":34},"2024-06-13",{"date":327,"type":22},"2024-06-02",{"date":329,"type":22},"2024-12-17",{"name":40,"class":41},{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":339,"maxAge":340,"enrollmentInfo":341,"targetDuration":342,"studyType":103,"phases":4,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100548810","virtual-reality-in-the-management-of-painful-or-anxiety-provoking-procedures-in-emergency-departments-100548810","NCT06425835","Virtual Reality in the Management of Painful or Anxiety-provoking Procedures in Emergency Departments","Virtual Reality in the Management of Painful or Anxiety-provoking Procedures in Emergency Departments: (Open Prospective Observational Study)","VR","Inclusion Criteria:\n\n* Patients aged 09 and 24 years\n* suturing a wound\n* changing a dressing\n* lumbar puncture,\n* peripheral venous line\n* blood test\n* intramuscular injection\n* reduction of a fracture\n* casting or plastering.\n\nExclusion Criteria:\n\n* impaired consciousness\n* epilepsy\n* wound\u002Finfection covering the helmet area\n* headache\n* intellectual\u002Fmental retardation\n* nausea, vomiting\n* patient already included in the protocol\n* pain requiring immediate medical attention. analgesic (VAS \\>5 and described as intolerable).","9 Years","24 Years",{"count":51,"type":22},"2 Years","Study and evaluate the effectiveness of virtual reality in pain management.",[345,346,347],"Pain and Anxiety","Dislocation","Suture","2024-05-21",{"date":350,"type":34},"2024-05-22",{"date":352,"type":22},"2024-08-15",{"date":354,"type":22},"2026-12-15",{"name":40,"class":41},{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":360,"conditions":367,"keywords":369,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":380,"locationsCount":65},"100464275","phase-3-intravenous-magnesium-sulfate-vs-placebo-to-treat-non--traumatic-acute-headaches-in-the-emergency-department-100464275","NCT05325580","Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department","Intravenous Magnesium Sulfate Vs Placebo to Treat Non-traumatic Acute Headaches in the Emergency Department","Inclusion Criteria:\n\n* informed consent\n* age \\>18 years\n* Acute non-traumatic acute headaches\n* patients treated in ED\n* Magnesium sulfate and aspirin administered intravenously (IV)\n\nExclusion Criteria:\n\n* Current regular use of analgesics, anticonvulsants or antidepressants\n* Renal disorder with a low glomerular filtration rate (\\\u003C60 ml\u002Fmin)\n* Neuromuscular disorder\n* Pregnant woman\n* Contrindication\n* Allergy to NSAID\n* Traumatic Headache\n* Chronic headache ( headache occurring at least 15 days per month for at least 3 months)\n* Hemodynamic instability","85 Years",{"count":365,"type":22},424,[25],[368],"Head Pain",[370,371,372,373,241],"intavenous","magnesium sulfate","nontraumatic","acute headaches","2024-02-27",{"date":376,"type":34},"2024-02-28",{"date":378,"type":34},"2021-12-01",{"date":121,"type":22},{"name":40,"class":41},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":65},"100494792","phase-2-oral-nsai-versus-acetaminophen-or-placebo-as-a-discharge-treatment-of-non-complicated-renal-colics-100494792","NCT05722782","Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics","The Investigation of the Efficacity and Safety of Oral Non Steroidal Anti Inflammatory (NSAI) Drugs Such as Piroxicam as a Second Line Treatment of Patients Consulting the Emergency Department for Renal Colics","NAP-RC","Inclusion Criteria:\n\n* Over 18 years old\n* Consenting to participate in the study\n* Patients treated in the ED for RC\n* No contraindications of NSAI or paracetamol treatment\n\nExclusion Criteria:\n\n* Contraindication of NSAI treatment\n* Patients non reachable by telephone call\n* Patients that did not receive or use the treatment",{"count":158,"type":22},[160],"Treatment with NSAI in renal colics has not been well investigated and there is no clear recommendations regarding this subject.\n\nThe aim of this study is to determine if an oral NSAI treatment is beneficial in patients discharged for the emergency department after the first line treatment of a renal colic investigating the reccurence of pain, the reconsultation rates and the admissions.",[55],[55,394,395],"NSAI","Acetaminophen","2023-11-13",{"date":398,"type":34},"2023-11-14",{"date":400,"type":34},"2023-07-01",{"date":402,"type":22},"2027-12",{"name":40,"class":41},""]